GNLX earnings analysis
What we found in GNLX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not include the income statement, balance sheet or cash-flow statements, so current-quarter revenue, margins, EPS, cash burn and segment trends cannot be assessed from the available filing text. Management reported effective disclosure controls as of June 30, 2026 and no material changes in internal controls. The principal filing update was a new trade-policy risk, including potential 100% tariffs on certain pharmaceutical products and ingredients; no quantitative outlook was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls Remained Effective
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
- No Material Control Changes
- The company reported no changes during the period covered by the 10-Q that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Potential 100% Pharmaceutical Tariffs
- The company added a material risk related to international trade policies. It stated that a presidential proclamation will impose 100% tariffs on certain patented pharmaceutical products and associated ingredients, potentially increasing R&D costs, disrupting supply chains and delaying development timelines.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q; no change to prior guidance can be determined.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Genelux Corporation reported a challenging quarter with no revenue generation, resulting in a net loss of $8.9 million, worsening from a loss of $7.5 million year-over-year. Operating expenses increased by approximately…
- 10-K · March 19, 2026
- Genelux is a late-stage oncolytic viral immunotherapy company advancing Olvi-Vec through a registrational Phase 3 (OnPrime/GOG-3076) in platinum-resistant/refractory ovarian cancer and ongoing systemic trials in NSCLC…
- 10-Q · November 5, 2025
- Genelux reported Q3 2025 GAAP net loss of $7,950 and EPS of $(0.21), slightly ahead of consensus $(0.22). Revenue remained $0 for the quarter; operating expenses rose to $8,194 driven by higher R&D and G&A. Management…
- 10-Q · August 7, 2025
- Genelux reported Q2 2025 net loss of $7,456,000 (GAAP loss per share $0.20) on revenue of $0.00. Operating expenses increased to $7,792,000 for the quarter (R&D $4,758,000; G&A $3,034,000). As of June 30, 2025 the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GNLX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever